<DOC>
	<DOCNO>NCT01482364</DOCNO>
	<brief_summary>The purpose study demonstrate monitor hemodynamic parameter apply predefined algorithm drug selection ( i.e . integrate hemodynamic management - IHM ) improve control systolic blood pressure ( SBP ) ambulatory blood pressure monitoring ( ABPM ) hypertensive patient , compare classical drug selection ( i.e . without IHM ) 6 month intensive treatment program .</brief_summary>
	<brief_title>BEtter Control Blood Pressure Hypertensive pAtients Monitored Using HOTMAN® sYstem</brief_title>
	<detailed_description>Early BP control hypertensives guarantee best prevention cardiovascular event long term ( 2007 ESH-ESC Guidelines Management Hypertension ; VALUE study ) . However , spite education effort antihypertensive drug , blood pressure control rate remain low . The common cause uncontrolled BP inadequate pharmacological treatment , selection antihypertensive agent often do independently hemodynamic status patient ( volemia , peripheral resistance , cardiac inotropy , heart rate ) . Several study confirm value use impedance cardiography ( ICG ) -derived hemodynamic data adjunct therapeutic decision-making treatment hypertension . Working hypothesis : possible ass hemodynamic status , select accordingly appropriate pharmacological class antihypertensive treatment , BP reduction occur great extent rapidly . In present study integrate therapeutic approach ( IHM-Integrated Hemodynamic Management ) apply , aim detect permanent vasoconstriction and/or hypervolemia and/or hyperinotropy HOTMAN System , order select appropriate antihypertensive drug .</detailed_description>
	<criteria>patient either sex present essential hypertension sustain hypertension office BP ( SBP &gt; 140 mmHg ) ABPM ( SBP &gt; 135 mmHg daytime ) treat 2 4 antihypertensive drug age ≥ 18 ≤ 75 year signature Informed Consent Form ( ICF ) pregnant lactate female type 1 diabetes patient pacemaker ( ventricular/dual chamber ) Severe aortic insufficiency severe hypertension ( SBP ≥ 180 mmHg and/or DBP ≥110 mmHg ) resistant hypertension require least 5 antihypertensive drug secondary hypertension aetiology , renal disease , pheocromocytoma , Cushing 's syndrome serious disorder may limit ability evaluate efficacy safety protocol , include cerebrovascular , cardiovascular , renal , respiratory , hepatic , gastrointestinal , endocrine , metabolic ( criterion metabolic syndrome ) , haematological , oncological , neurological , psychiatric disease history follow pathology within last 6 month : myocardial infarction unstable angina pectoris percutaneous coronary intervention bypass surgery congestive heart failure stage IIIIV leave branch bundle block atrial fibrillation hypertensive encephalopathy stroke extreme obesity ( BMI &gt; 35 ) previously enrol subject alcohol drug abuse past 2 year plan hospitalization study period participation clinical study within 30 day prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HOTMAN System</keyword>
	<keyword>Hemodynamic integrate management</keyword>
</DOC>